Asia Pacific Insulin Market Review to 2018 – Transition from Human Insulin to Analog Insulin - Ken Research

MenuMenu

Asia Pacific Insulin Market Review to 2018 – Transition from Human Insulin to Analog Insulin

REQUEST FOR SAMPLE REPORT

Asia Insulin Market Research Report presents a comprehensive analysis of market size by value of major types of insulin consumed in Asia Pacific region. The report entails the market share analysis of major insulin brands in premix insulin, long acting and rapid acting insulin category and company profiles of major players in the insulin market in India, China and Japan. The future analysis has also been discussed in each market.

Insulin Market in Asia PacificThe worldwide prevalence of diabetes was estimated to be ~ million in 2013 and is expected to soar 55%, reaching to 591.1 million patients by 2035. The primary determinants of diabetes are the rapid epidemiological transition associated with changes in dietary patterns and decreased physical activity. Nearly 5.1 million deaths in the world occurred due to diabetes in 2013. Low and middle income countries are host to almost 80.0% of the total diabetic cases in the world. However, diabetes imposes unacceptably high human, social and economic costs on countries at all income levels. The disease is observed to be most prevalent in Asia Pacific that includes the fastest growing economies globally. China and India are representatives of the above mentioned fact and have the highest number of people with diabetes in the world.

Since the Asian countries reside majorly in the middle income group, diagnosis and treatment of diabetes does not reach to a large part of the population. Lack of awareness and affordability are the biggest hindrances to curbing diabetes in the region. Nevertheless, due to increasing level of education and consciousness in the Asian countries, people are gradually paying more attention to diabetes care and diagnosis.

The world’s largest diabetic population resides in Asia Pacific due to which the demand for insulin is on a constant rise. Japan, China and India are the important markets in the region. The revenue generated by the insulin market in Asia Pacific in 2013 was estimated to be USD ~ million and registered a CAGR of ~% during 2008-2013. Japan adds the highest value to the regional market through the sale of high priced premium products. However, China is set to become the largest contributing market in the near future.

The global insulin market is distinctively dominated by 3 companies, namely Novo Nordisk from Denmark, Eli Lilly from the US and France’s Sanofi Aventis. A cumulative average of ~% of the market in every country is captured by these three companies. Regional players such as Biocon and Wockhardt in India and Shanghai Fosun Pharmaceuticals and Tonghua Dongbao in China have a minor stake in the countries’ respective insulin markets. Companies in the Asian region are consistently engaged in extensive R&D to introduce new products that are conducive to the local requirements. Furthermore, expiration of patents of several major brands of insulin in the recent future is expected to intensify competition in Asia Pacific. Launch of generic versions of the existing insulin brands in the coming years will lead to change in market shares of some of the leading insulin brands in the region.

Key Topics Covered in the Report:

  • The market size of Asia insulin market in terms of revenue
  • Asian market segmentation by geographies covering China, India and Japan, by insulin replacement therapy and types of insulin
  • Trends, growth drivers and challenges in Asia insulin market
  • Product Pipeline of major insulin companies
  • Future outlook and projections of the insulin market in Asia
  • India insulin market size, segmentation by insulin replacement therapy and types of insulin, pricing scenario, trends, growth drivers and issues, market share of major companies in the market
  • China insulin market size, segmentation by insulin replacement therapy and types of insulin, trends and growth drivers, market share of major companies in the market
  • Government regulations and support schemes in India and China insulin market
  • Japan insulin market size, segmentation by insulin replacement therapy and types of insulin, trends and growth drivers, market share of major companies in the market
  • Profiles of major companies in India, China and Japan insulin market
  • Future Outlook and macroeconomic factors in insulin market in China, India and Japan

List of Tables:

Table 1: Top 10 Countries with the Largest Diabetic Population Globally, 2013

Table 2: Asia Pacific Insulin Market Segmentation on the Basis of Revenue of Different Geographies in USD Million, 2008-2013

Table 3: Asia Pacific Insulin Market Segmentation by Insulin Replacement Therapy (Human Insulin and Analog Insulin) on the Basis of Revenue in USD Million, 2013

Table 4: Asia Insulin Market Segmentation by Types of Insulin (Premix, Rapid Acting and Long Acting) on the Basis of Revenue in USD Million, 2013

Table 5: New Insulin Development by Major Insulin Companies

Table 6: Mean Diabetes Related Expenditure Per Person with Diabetes in USD, 2012-2013

Table 7: SWOT Analysis of Asia Insulin Market

Table 8: Asia Pacific Insulin Market Future Projection by Geography on the Basis of Revenue in USD Million, 2014-2018

Table 9: India Insulin Market Segmentation by Insulin Replacement Therapy (Human Insulin and Analog Insulin) on the Basis of Revenue in USD Million, FY’2008-FY’2013

Table 10: India Insulin Market Segmentation by Type of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Revenue in USD Million, FY’2008-FY’2013

Table 11: India Insulin Market Segmentation by Type 1 and Type 2 Diabetes on the Basis of Revenue in USD Million, FY’2013

Table 12: Price Ceiling for Domestically Manufactured Insulin

Table 13: Price Ceiling for Imported Insulin

Table 14: Prices of Various Insulin Brands in India

Table 15: Revenue Contribution of Major Companies in India Insulin Market in USD Million, FY’2013

Table 16: Revenue of Major Companies in India Premix Insulin Market by Brands in USD Million, FY’2013

Table 17: Revenue of Major Companies in India Long Acting Insulin Market by Brands in USD Million, FY’2013

Table 18: Revenue of Major Companies in India Rapid Acting Insulin Market by Brands in USD Million, FY’2013

Table 19: India Insulin Market Future Projections on the Basis of Revenue by Insulin Replacement Therapy in USD Million, FY’2014-FY’2018

Table 20: Cause and Effect Relationship between the Dependent and Independent Variables Prevailing in India Insulin Market

Table 21: China Insulin Market Segmentation by Insulin Replacement Therapy (Human Insulin and Analog Insulin) on the Basis of Revenue in USD Million, 2008-2013

Table 22: China Insulin Market Segmentation by Type of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Consumption Volume in Thousand of Million Units (tMU), 2008-2013

Table 23: China Insulin Market Segmentation by Types of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Revenue in USD Million, 2008-2013

Table 24: China Insulin Market Segmentation by Type 1 and Type 2 Diabetes on the Basis of Revenue in USD Million, 2013

Table 25: Patent Expiry for Major Insulin Brands in China

Table 26: Revenue of Major Companies in China Insulin Market in USD Million, 2013

Table 27: Market Share of Major Companies in China Insulin Market on the Basis of Volume in tMU, 2010-2013

Table 28: Revenue of Major Companies in China Human Insulin Market in USD Million, 2010 and 2013

Table 29: Revenue of Major Companies in China Analog Insulin Market in USD Million, 2010 and 2013

Table 30: Brand-wise Revenue of Major Companies in China Premix Insulin Market in USD Million, 2013

Table 31: Brand-wise Revenue of Major Long Acting Insulin Brands in China in USD Million, 2013

Table 32: Brand-wise Revenue of Major Rapid Acting Insulin Brands in China in USD Million, 2013

Table 33: Lantus Sales in China in USD Million, 2009-2013

Table 34: China Insulin Market Future Projections on the Basis of Revenue by Insulin Replacement Therapy in USD Million, 2014-2018

Table 35: China Insulin Market Future Projections on the Basis of Revenue by Insulin Type of Insulin in USD Million, 2014-2018

Table 36: Cause and Effect Relationship between the Dependent and Independent Variables Prevailing in India Insulin Market

Table 37: Japan Insulin Market Segmentation by Insulin Replacement Therapy (Human Insulin and Analog Insulin) on the Basis of Revenue in USD Million, 2013

Table 38: Japan Insulin Market Segmentation by Type of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Consumption Volume in Thousand Million Units (tMU), 2008-2013

Table 39: Japan Insulin Market Segmentation by Type of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Revenue in USD Million, 2013

Table 40: Patent Expiry for Major Insulin Brands in Japan

Table 41: Japan Population by Different Age Group in Million, 2008-2013

Table 42: Market Share of Major Companies in China Insulin Market on the Basis of Volume in tMU, 2010-2013

Table 43: Competitive Landscape of Major Players in Japan Insulin Market

Table 44: Cause and Effect Relationship between the Dependent and Independent Variables Prevailing in Japan Insulin Market

Table 45: Correlation Matrix of India Insulin Market

Table 46: Regression Coefficients Output

Browse and Download Report Here-http://www.kenresearch.com/healthcare/pharmaceutical-industry/asia-pacific-insulin-market-research-report/572-91.html

Contact:
Ken Research
Information Department
info@kenresearch.com
+91-011-47017199

Tags: , , , , , , , , , , ,

scroll to top